US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
- Founded
- 2016
- Employees
- 9
- Programs
- 99
- Drugs
- 26
- Patents
- 0
Lakefront Biotherapeutics NV pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lakefront Biotherapeutics NV drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
ambrisentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
filgotinib
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Lakefront Biotherapeutics NV's portfolio. Molecular target: Tyrosine-protein kinase JAK1.
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK3 inhibitor
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
pirfenidone
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.
-
Development asset linked to Lakefront Biotherapeutics NV in public FDA and regional records.